Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)
Photo courtesy of Brittany

Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)

Before you read further, make sure to check out Part 1 of our interview, where Brittany discusses what non-small cell lung cancer (NSCLC) is, her diagnostic journey, and how she learned that…

Continue Reading Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)
Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)
Photo courtesy of Brittany

Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)

On the one-year anniversary of her RET+ non-small cell lung cancer (NSCLC) diagnosis, 37-year-old Brittany Hawkins had spent some time reflecting on her journey. When she was just seventeen years…

Continue Reading Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)
Researchers Identify New Pediatric Rare Disease: Neuro-Ocular DAGLA-Related Syndrome (NODRS)
source: pixabay.com

Researchers Identify New Pediatric Rare Disease: Neuro-Ocular DAGLA-Related Syndrome (NODRS)

More rare conditions are discovered as we learn more about the human body and genetics. For example, shares an article in Medical XPress, a research team from the University of…

Continue Reading Researchers Identify New Pediatric Rare Disease: Neuro-Ocular DAGLA-Related Syndrome (NODRS)

Will This Novel Drug That Utilizes AI Succeed in Having an Impact on ALS When so Many Others Have Failed?

Verge Genomics, based in San Francisco is one of a series of biotechs that have entered into a new era using AI in drug discovery. The company is backed by…

Continue Reading Will This Novel Drug That Utilizes AI Succeed in Having an Impact on ALS When so Many Others Have Failed?